Insights & Resources

Rising physician compensation and growing financial losses are putting health systems under pressure. Explore the 2024 trends and valuation insights.

The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.

New York’s business interruption law introduced new stand-alone coverage opportunities, providing businesses options for tailored protection.

Shale maturation and technological innovation impact IP valuations, influencing long-term asset value and productivity in the oil and gas industry.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.

The biopharma industry has experienced a resurgence the first part of 2024. J.P. Morgan’s Q2 report shares critical insights into the future of the industry.

Ardent Health’s recent IPO highlights the company’s unique qualities, though it creates valuation comparability challenges for joint ventures and leased facilities.

New standards for internal audit are scheduled to take effect January 2025 as the industry embraces a more comprehensive approach to the professional practice.

The instances of urgent care clinic visits have returned to pre-pandemic levels, but COVID-related services still make up a large percentage of the total volume.

PCI DSS sets the standard for payment card security in higher education detailing compliance levels, reporting requirements and strategies to protect data.

Managing revenue cycles is an important aspect of modern hospital operations. Defined business processes and strong internal controls are the keys to optimization.

The home health and hospice sectors are facing significant challenges with personal care emerging as the key sector for mitigating risk.